![Sanofi Genzyme and Dimock Center named Boston Business Journal Partners of the Year - Boston Business Journal Sanofi Genzyme and Dimock Center named Boston Business Journal Partners of the Year - Boston Business Journal](https://media.bizj.us/view/img/11022470/sanofi-genzyme-service-day-0716*750xx3264-1836-0-306.jpg)
Sanofi Genzyme and Dimock Center named Boston Business Journal Partners of the Year - Boston Business Journal
![Sanofi on Twitter: "#RSV is a common respiratory virus, affecting 90% of children before the age of two. While RSV is mild for most, it can be severe for some and lead Sanofi on Twitter: "#RSV is a common respiratory virus, affecting 90% of children before the age of two. While RSV is mild for most, it can be severe for some and lead](https://pbs.twimg.com/media/E487a3AX0AEpJHh.jpg)
Sanofi on Twitter: "#RSV is a common respiratory virus, affecting 90% of children before the age of two. While RSV is mild for most, it can be severe for some and lead
![Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi Espoir Corporate Foundation | EuropaWire.eu | The European Union's press release distribution & newswire service Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi Espoir Corporate Foundation | EuropaWire.eu | The European Union's press release distribution & newswire service](https://news.europawire.eu/wp-content/uploads/2020/09/Sanofi-Dr-Rufin.jpg)
Dr. Jean-Christophe Rufin to succeed Xavier Darcos as President of Sanofi Espoir Corporate Foundation | EuropaWire.eu | The European Union's press release distribution & newswire service
![Pharmaceutical French group Sanofi-Aventis Chairman Jean-Francois Dehecq (L) listens to Gerard Le Fur (R), Executive Vice President for Scientific and Medical Operations, during a press conference to present the full-year 2005 results. Pharmaceutical French group Sanofi-Aventis Chairman Jean-Francois Dehecq (L) listens to Gerard Le Fur (R), Executive Vice President for Scientific and Medical Operations, during a press conference to present the full-year 2005 results.](https://c8.alamy.com/comp/2E95WGA/pharmaceutical-french-group-sanofi-aventis-chairman-jean-francois-dehecq-l-listens-to-gerard-le-fur-r-executive-vice-president-for-scientific-and-medical-operations-during-a-press-conference-to-present-the-full-year-2005-results-sanofi-aventis-announced-a-series-of-positive-drug-research-developments-in-paris-on-february-24-2006-photo-by-christophe-guibbaudabacapresscom-2E95WGA.jpg)
Pharmaceutical French group Sanofi-Aventis Chairman Jean-Francois Dehecq (L) listens to Gerard Le Fur (R), Executive Vice President for Scientific and Medical Operations, during a press conference to present the full-year 2005 results.
![Sanofi on Twitter: "“Our chlamydia research is on track to support the initiation of a first clinical trial for the chlamydia-based multivalent candidate in 2023.” - Jean-François Toussaint #SanofiVaccines https://t.co/pYePCiJSd7" / Twitter Sanofi on Twitter: "“Our chlamydia research is on track to support the initiation of a first clinical trial for the chlamydia-based multivalent candidate in 2023.” - Jean-François Toussaint #SanofiVaccines https://t.co/pYePCiJSd7" / Twitter](https://pbs.twimg.com/media/FFiGne3X0AISBYZ.jpg:large)